Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients

Martina L. Reichmuth, Rico Hömke, Kathrin Zürcher, Peter Sander, Anchalee Avihingsanon, Jimena Collantes, Chloé Loiseau, Sonia Borrell, Miriam Reinhard, Robert J. Wilkinson, Marcel Yotebieng, Lukas Fenner, Erik C. Böttger, Sebastien Gagneux, Matthias Egger, Peter M. Keller
Martina L. Reichmuth
aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Martina L. Reichmuth
Rico Hömke
bInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland
cSwiss National Center for Mycobacteria, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathrin Zürcher
aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Sander
bInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland
cSwiss National Center for Mycobacteria, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter Sander
Anchalee Avihingsanon
dThe HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jimena Collantes
eInstituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chloé Loiseau
fSwiss Tropical and Public Health Institute, Basel, Switzerland
gUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonia Borrell
fSwiss Tropical and Public Health Institute, Basel, Switzerland
gUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miriam Reinhard
fSwiss Tropical and Public Health Institute, Basel, Switzerland
gUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert J. Wilkinson
hWellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, Republic of South Africa
iDepartment of Infectious Diseases, Imperial College, London, United Kingdom
jThe Francis Crick Institute, London, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcel Yotebieng
kNational TB Lab, Kinshasa, Democratic Republic of the Congo
lAlbert Einstein College of Medicine, New York, New York, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lukas Fenner
aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lukas Fenner
Erik C. Böttger
bInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland
cSwiss National Center for Mycobacteria, Zurich, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastien Gagneux
fSwiss Tropical and Public Health Institute, Basel, Switzerland
gUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Egger
aInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland
mCentre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, Republic of South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter M. Keller
bInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland
cSwiss National Center for Mycobacteria, Zurich, Switzerland
nInstitute for Infectious Diseases, University of Bern, Bern, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Peter M. Keller
DOI: 10.1128/AAC.00513-20
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Mutations in the genes of the F420 signaling pathway of Mycobacterium tuberculosis complex, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, can lead to delamanid resistance. We searched for such mutations among 129 M. tuberculosis strains from Asia, South America, and Africa using whole-genome sequencing; 70 (54%) strains had at least one mutation in one of the genes. For 10 strains with mutations, we determined the MIC of delamanid. We found one strain from a delamanid-naive patient carrying the natural polymorphism Tyr29del (ddn) that was associated with a critical delamanid MIC.

TEXT

In 2014, the new antituberculosis (anti-TB) drug delamanid (also known as OPC-67683, or Deltyba) was introduced (1). The World Health Organization (WHO) recommends the administration of delamanid if a standard effective drug regimen cannot be prescribed due to drug toxicity or resistance (2, 3). Thus, the European Medicines Agency (EMA) conditionally approved delamanid for the treatment of multidrug-resistant (MDR) TB (1, 3, 4). Of note, 6 years after its market launch, robust and widely accepted breakpoints that define susceptibility and resistance to delamanid still do not exist (5). The few available studies suggest a critical MIC between 0.125 mg/liter and 0.2 mg/liter, and an epidemiological cutoff value (ECOFF) of 0.04 mg/liter (6–9). This ECOFF is in line with the WHO technical report (10).

Delamanid is a drug of the bicyclic nitroimidazole class with potent anti-TB activity (1, 11). It is a prodrug that is activated by the deazaflavin (F420)-dependent nitroreductase (ddn) through hydride transfer, forming unstable intermediates, which in turn lead to the formation of reactive nitrogen species (nitric oxide, nitrous acid) (12, 13). Activated delamanid thus has a dual bactericidal mode of action: the primary decomposition product prevents mycolic acid synthesis, while the reactive nitrogen species cause respiratory poisoning (12–15). Loss-of-function mutations in ddn or one of the genes encoding the five coenzymes (fgd1, fbiA, fbiB, fbiC, and fbiD) have been proposed as a mechanism of resistance to delamanid (12, 13, 16, 17). In vitro, the frequencies of delamanid resistance-conferring mutations in the Mycobacterium tuberculosis laboratory strain H37Rv and in Mycobacterium bovis range from 2.51 × 10−5 to 6.44 × 10−6 (13). Previous studies have found several resistance-conferring mutations, including Leu107Pro (ddn), 51–101del (ddn), Trp88STOP (ddn), Gly81Asp (ddn), Gly81Ser (ddn), Gly53Asp (ddn), c.146_147insC (fgd1), Gln88Glu (fgd1), Lys250STOP (fbiA), Arg175His (fbiA), and Val318Ile (fibC) (6–8, 18–22).

This multicenter study has been described in detail elsewhere and is part of the work of the International epidemiology Databases to Evaluate AIDS (IeDEA) (23). We identified putative delamanid resistance-conferring mutations in M. tuberculosis strains from TB patients living with HIV (PLWH) and delamanid-naive, HIV-negative TB patients by whole-genome sequencing (WGS) and MIC determination. We collected information on the demographic and clinical characteristics of patients who were recruited between 2013 and 2016 in Peru, Thailand, Côte d’Ivoire, the Democratic Republic of the Congo (DRC), Kenya, and South Africa (24, 25). The Cantonal Ethics Committee in Bern, Switzerland, and local institutional review boards approved the study. Written informed consent was obtained at all locations, except in South Africa, where consent was not required for archived samples.

The sequencing pipeline has been described previously (25). In brief, M. tuberculosis DNA was extracted and sequenced using the Illumina HiSeq 2500 system (Illumina, San Diego, CA, USA). For the analysis, we used the well-established pipeline TBprofiler (https://github.com/jodyphelan/TBProfiler) (26, 27). It aligns short reads to the M. tuberculosis reference strain H37Rv (GenBank accession no. NC_000962.3) with bowtie2 (v2.3.5), BWA (v0.7.17), or minimap2 (v2.16) and then calls variants with SAMtools (v1.9) (28–31). To identify putative delamanid resistance-conferring mutations, we analyzed F420 genes (ddn, fgd1, fbiA, fbiB, fbiC, and fbiD) with variant frequencies of ≥75%. A subset of M. tuberculosis strains with at least one mutation in the F420 genes was recultured in liquid medium and subjected to delamanid MIC determination (see Fig. S1 in the supplemental material). We assumed that 0.04 mg/liter indicates a critical MIC (9).

We included 129 M. tuberculosis isolates, among them 51 isolates (39.5%) from Peru, 13 (10.1%) from Thailand, 49 (38%) from Côte d’Ivoire, 14 (10.9%) from the DRC, and 1 (0.8%) each from Kenya and South Africa. We identified 70 (54.3%) isolates with polymorphisms in at least one of the six F420 genes compared to the reference genome (Table S1). All patients infected with either of these strains were naive to delamanid. We selected strains fulfilling the following criteria: (i) mutations in a part of the gene encoding regions of catalytic or structural importance predicted by ARIBA and then the PhyResSE pipeline (32, 33), (ii) availability of a culture of the strain, and (iii) bacterial growth amenable to microdilution (25). MICs were determined for 10 isolates with mutations in the F420 genes. Four isolates showed MICs of >0.015 mg/liter: specifically, MICs of 0.5 (patient 1), 0.03 (patients 6 and 10), and >8 (patient 9) mg/liter (Table 1; Fig. S1). The isolate from patient 1 had a polymorphism in fgd1 (Lys270Met) and was susceptible to the six drugs tested (isoniazid, rifampin, ethambutol, pyrazinamide, moxifloxacin, and amikacin). The patient was cured. The isolate from patient 9 had two alterations: a deletion in ddn (Tyr29del) and a nucleotide change in fgd1 (T960C). The strain showed an elevated delamanid MIC and was phenotypically susceptible to six other drugs tested. The patient died. The MIC for the isolates of patients 10 and 6 was above 0.015 but below 0.04 mg/liter (Table 1). This suggests low-level resistance to delamanid (22), which could be due to the combination of various mutations: Ala416Val (fbiC), Trp678Gly (fbiC), Arg64Ser (fgd1), and T960C (fgd1).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

Observed polymorphisms in F420 genes and MIC values of delamanida

In summary, in the subset of 10 isolates with polymorphisms in the six targeted genes, six had no elevated MIC in the microdilution, while four isolates had elevated MICs (Table 1). In line with previous studies, we found that Lys270Met in fgd1 is a natural polymorphism characteristic of M. tuberculosis lineage 4.1.2.1, which may (patients 1 and 6) or may not (patient 7) lead to an increased delamanid MIC (19, 34, 35). All 16 strains of lineage 4.1.2.1 showed this lineage-specific marker (Table S1). Furthermore, T960C (fgd1) is a synonymous substitution and was found in three other patient isolates which, as expected, did not have a critical MIC. The increase in the delamanid MIC for the isolate of patient 9 was due to the deletion in ddn (7). Our results thus suggest that Tyr29del is a natural polymorphism leading to an increased delamanid MIC. Our study was too small to estimate the prevalence of strains that are naturally resistant to delamanid. In 2020, Lee et al. screened 14,876 M. tuberculosis strains and found 2 strains with Tyr29del, for a prevalence of 0.013% (36). However, in their study, only the ddn gene was screened, and the prevalence of natural resistance could, therefore, be higher.

In conclusion, we confirm that mutations in F420 genes can confer an elevated delamanid MIC (13, 19). Whether our findings also apply to the related drug pretomanid should be investigated in future studies. The occurrence of clinical M. tuberculosis isolates from previously untreated patients for which delamanid MICs are naturally elevated calls for careful drug susceptibility testing (DST) prior to delamanid treatment (5, 36). However, access to DST is limited in high-burden countries. This dilemma highlights the conflict between making new drugs available in high-burden countries and avoiding the spread of drug-resistant strains.

Data availability.WGS data from patients’ M. tuberculosis strains shown in Table 1 have been submitted to the NCBI (BioProject accession no. PRJNA300846) (Table S1).

ACKNOWLEDGMENTS

We thank those at all sites who participated, the patients whose data were used in this study, and Marie Ballif for contributing to the data collection and for critical reading of the manuscript. Calculations were performed on UBELIX (http://www.id.unibe.ch/hpc), the HPC cluster at the University of Bern.

This research was supported by the Swiss National Foundation (project grants 153442, 310030_166687, 310030_188888, IZRJZ3_164171, IZLSZ3_170834, and CRSII5_177163). The International epidemiology Databases to Evaluate AIDS (IeDEA) is supported by the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Cancer Institute, National Institute of Mental Health, National Institute on Drug Abuse, National Heart, Lung, and Blood Institute, National Institute on Alcohol Abuse and Alcoholism, National Institute of Diabetes and Digestive and Kidney Diseases, Fogarty International Center, and National Library of Medicine (Asia- Pacific, U01AI069907; CCASAnet, U01AI069923; Central Africa, U01AI096299; East Africa, U01AI069911; NA-ACCORD, U01AI069918; Southern Africa, U01AI069924; West Africa, U01AI069919). R.J.W. receives support from the Francis Crick Institute, which is funded by UKRI, CRUK, and the Wellcome Trust (grants FC0010218, 104803, and 203135). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned above.

We have no potential conflicts of interest to disclose.

FOOTNOTES

    • Received 9 April 2020.
    • Returned for modification 6 July 2020.
    • Accepted 19 August 2020.
    • Accepted manuscript posted online 31 August 2020.
  • Supplemental material is available online only.

  • Copyright © 2020 Reichmuth et al.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

REFERENCES

  1. 1.↵
    1. Liu Y,
    2. Matsumoto M,
    3. Ishida H,
    4. Ohguro K,
    5. Yoshitake M,
    6. Gupta R,
    7. Geiter L,
    8. Hafkin J
    . 2018. Delamanid: from discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB). Tuberculosis (Edinb) 111:20–30. doi:10.1016/j.tube.2018.04.008.
    OpenUrlCrossRef
  2. 2.↵
    1. Esmail A,
    2. Sabur NF,
    3. Okpechi I,
    4. Dheda K
    . 2018. Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill. J Thorac Dis 10:3102–3118. doi:10.21037/jtd.2018.05.11.
    OpenUrlCrossRef
  3. 3.↵
    WHO. 2019. Consolidated guidelines on drug-resistant tuberculosis treatment. World Health Organization, Geneva, Switzerland.
  4. 4.↵
    EMA. 2018. Deltyba (delamanid): an overview of Deltyba and why it is authorised in the EU. European Medicines Agency, London, United Kingdom.
  5. 5.↵
    1. Köser CU,
    2. Maurer FP,
    3. Kranzer K
    . 2019. ‘Those who cannot remember the past are condemned to repeat it’: drug-susceptibility testing for bedaquiline and delamanid. Int J Infect Dis 80S:S32–S35. doi:10.1016/j.ijid.2019.02.027.
    OpenUrlCrossRef
  6. 6.↵
    1. Stinson K,
    2. Kurepina N,
    3. Venter A,
    4. Fujiwara M,
    5. Kawasaki M,
    6. Timm J,
    7. Shashkina E,
    8. Kreiswirth BN,
    9. Liu Y,
    10. Matsumoto M,
    11. Geiter L
    . 2016. MIC of delamanid (OPC-67683) against Mycobacterium tuberculosis clinical isolates and a proposed critical concentration. Antimicrob Agents Chemother 60:3316–3322. doi:10.1128/AAC.03014-15.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Schena E,
    2. Nedialkova L,
    3. Borroni E,
    4. Battaglia S,
    5. Cabibbe AM,
    6. Niemann S,
    7. Utpatel C,
    8. Merker M,
    9. Trovato A,
    10. Hofmann-Thiel S,
    11. Hoffmann H,
    12. Cirillo DM
    . 2016. Delamanid susceptibility testing of Mycobacterium tuberculosis using the resazurin microtitre assay and the BACTEC MGIT 960 system. J Antimicrob Chemother 71:1532–1539. doi:10.1093/jac/dkw044.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Hoffmann H,
    2. Kohl TA,
    3. Hofmann-Thiel S,
    4. Merker M,
    5. Beckert P,
    6. Jaton K,
    7. Nedialkova L,
    8. Sahalchyk E,
    9. Rothe T,
    10. Keller PM,
    11. Niemann S
    . 2016. Delamanid and bedaquiline resistance in Mycobacterium tuberculosis ancestral Beijing genotype causing extensively drug-resistant tuberculosis in a Tibetan refugee. Am J Respir Crit Care Med 193:337–340. doi:10.1164/rccm.201502-0372LE.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Keller PM,
    2. Homke R,
    3. Ritter C,
    4. Valsesia G,
    5. Bloemberg GV,
    6. Böttger EC
    . 2015. Determination of MIC distribution and epidemiological cutoff values for bedaquiline and delamanid in Mycobacterium tuberculosis using the MGIT 960 system equipped with TB eXiST. Antimicrob Agents Chemother 59:4352–4355. doi:10.1128/AAC.00614-15.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    WHO. 2018. Technical report on critical concentrations for drug susceptibility testing of medicines used in the treatment of drug-resistant tuberculosis. WHO/CDS/TB/2018.5. World Health Organization, Geneva, Switzerland.
  11. 11.↵
    1. Matsumoto M,
    2. Hashizume H,
    3. Tomishige T,
    4. Kawasaki M,
    5. Tsubouchi H,
    6. Sasaki H,
    7. Shimokawa Y,
    8. Komatsu M
    . 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. doi:10.1371/journal.pmed.0030466.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Purwantini E,
    2. Mukhopadhyay B
    . 2009. Conversion of NO2 to NO by reduced coenzyme F420 protects mycobacteria from nitrosative damage. Proc Natl Acad Sci U S A 106:6333–6338. doi:10.1073/pnas.0812883106.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Fujiwara M,
    2. Kawasaki M,
    3. Hariguchi N,
    4. Liu Y,
    5. Matsumoto M
    . 2018. Mechanisms of resistance to delamanid, a drug for Mycobacterium tuberculosis. Tuberculosis (Edinb) 108:186–194. doi:10.1016/j.tube.2017.12.006.
    OpenUrlCrossRef
  14. 14.↵
    1. Greening C,
    2. Ahmed FH,
    3. Mohamed AE,
    4. Lee BM,
    5. Pandey G,
    6. Warden AC,
    7. Scott C,
    8. Oakeshott JG,
    9. Taylor MC,
    10. Jackson CJ
    . 2016. Physiology, biochemistry, and applications of F420- and Fo-dependent redox reactions. Microbiol Mol Biol Rev 80:451–493. doi:10.1128/MMBR.00070-15.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Van den Bossche A,
    2. Varet H,
    3. Sury A,
    4. Sismeiro O,
    5. Legendre R,
    6. Coppee JY,
    7. Mathys V,
    8. Ceyssens PJ
    . 2019. Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. Tuberculosis (Edinb) 117:18–23. doi:10.1016/j.tube.2019.05.002.
    OpenUrlCrossRef
  16. 16.↵
    1. Rifat D,
    2. Li S-Y,
    3. Ioerger T,
    4. Lanoix J-P,
    5. Lee J,
    6. Bashiri G,
    7. Sacchettini J,
    8. Nuermberger E
    . 2018. Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis. bioRxiv https://doi.org/10.1101/457754.
  17. 17.↵
    1. Bashiri G,
    2. Antoney J,
    3. Jirgis ENM,
    4. Shah MV,
    5. Ney B,
    6. Copp J,
    7. Stuteley SM,
    8. Sreebhavan S,
    9. Palmer B,
    10. Middleditch M,
    11. Tokuriki N,
    12. Greening C,
    13. Scott C,
    14. Baker EN,
    15. Jackson CJ
    . 2019. A revised biosynthetic pathway for the cofactor F420 in prokaryotes. Nat Commun 10:1558. doi:10.1038/s41467-019-09534-x.
    OpenUrlCrossRef
  18. 18.↵
    1. Bloemberg GV,
    2. Keller PM,
    3. Stucki D,
    4. Stuckia D,
    5. Trauner A,
    6. Borrell S,
    7. Latshang T,
    8. Coscolla M,
    9. Rothe T,
    10. Hömke R,
    11. Ritter C,
    12. Feldmann J,
    13. Schulthess B,
    14. Gagneux S,
    15. Böttger EC
    . 2015. Acquired resistance to bedaquiline and delamanid in therapy for tuberculosis. N Engl J Med 373:1986–1988. doi:10.1056/NEJMc1505196.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Feuerriegel S,
    2. Köser CU,
    3. Bau D,
    4. Rusch-Gerdes S,
    5. Summers DK,
    6. Archer JA,
    7. Marti-Renom MA,
    8. Niemann S
    . 2011. Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrob Agents Chemother 55:5718–5722. doi:10.1128/AAC.05500-11.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Yang JS,
    2. Kim KJ,
    3. Choi H,
    4. Lee SH
    . 2018. Delamanid, bedaquiline, and linezolid minimum inhibitory concentration distributions and resistance-related gene mutations in multidrug-resistant and extensively drug-resistant tuberculosis in Korea. Ann Lab Med 38:563–568. doi:10.3343/alm.2018.38.6.563.
    OpenUrlCrossRef
  21. 21.↵
    1. Pang Y,
    2. Zong Z,
    3. Huo F,
    4. Jing W,
    5. Ma Y,
    6. Dong L,
    7. Li Y,
    8. Zhao L,
    9. Fu Y,
    10. Huang H
    . 2017. In vitro drug susceptibility of bedaquiline, delamanid, linezolid, clofazimine, moxifloxacin, and gatifloxacin against extensively drug-resistant tuberculosis in Beijing, China. Antimicrob Agents Chemother 61:e00900-17. doi:10.1128/AAC.00900-17.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Polsfuss S,
    2. Hofmann-Thiel S,
    3. Merker M,
    4. Krieger D,
    5. Niemann S,
    6. Rüssmann H,
    7. Schönfeld N,
    8. Hoffmann H,
    9. Kranzer K
    . 2019. Emergence of low-level delamanid and bedaquiline resistance during extremely drug-resistant tuberculosis treatment. Clin Infect Dis 69:1229–1231. doi:10.1093/cid/ciz074.
    OpenUrlCrossRef
  23. 23.↵
    Antiretroviral Therapy in Low-Income Countries Collaboration of the International epidemiological Databases to Evaluate AIDS (IeDEA); ART Cohort Collaboration; Brinkhof MWG, Egger M, Boulle A, May M, Hosseinipour M, Sprinz E, Braitstein P, Dabis F, Reiss P, Bangsberg DR, Rickenbach M, Miro JM, Myer L, Mocroft A, Nash D, Keiser O, Pascoe M, van der Borght S, Schechter M. 2007. Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries. Clin Infect Dis 45:1518–1521. doi:10.1086/522986.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Zürcher K,
    2. Ballif M,
    3. Fenner L,
    4. Borrell S,
    5. Keller PM,
    6. Gnokoro J,
    7. Marcy O,
    8. Yotebieng M,
    9. Diero L,
    10. Carter EJ,
    11. Rockwood N,
    12. Wilkinson RJ,
    13. Cox H,
    14. Ezati N,
    15. Abimiku AG,
    16. Collantes J,
    17. Avihingsanon A,
    18. Kawkitinarong K,
    19. Reinhard M,
    20. Hömke R,
    21. Huebner R,
    22. Gagneux S,
    23. Böttger EC,
    24. Egger M
    , International epidemiological Databases to Evaluate AIDS (IeDEA) consortium. 2019. Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infect Dis 19:298–307. doi:10.1016/S1473-3099(18)30673-X.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Gygli SM,
    2. Keller PM,
    3. Ballif M,
    4. Blöchliger N,
    5. Homke R,
    6. Reinhard M,
    7. Loiseau C,
    8. Ritter C,
    9. Sander P,
    10. Borrell S,
    11. Collantes Loo J,
    12. Avihingsanon A,
    13. Gnokoro J,
    14. Yotebieng M,
    15. Egger M,
    16. Gagneux S,
    17. Böttger EC
    . 2019. Whole-genome sequencing for drug resistance profile prediction in Mycobacterium tuberculosis. Antimicrob Agents Chemother 63:e02175-18. doi:10.1128/AAC.02175-18.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Phelan JE,
    2. O’Sullivan DM,
    3. Machado D,
    4. Ramos J,
    5. Oppong YEA,
    6. Campino S,
    7. O’Grady J,
    8. McNerney R,
    9. Hibberd ML,
    10. Viveiros M,
    11. Huggett JF,
    12. Clark TG
    . 2019. Integrating informatics tools and portable sequencing technology for rapid detection of resistance to anti-tuberculous drugs. Genome Med 11:41. doi:10.1186/s13073-019-0650-x.
    OpenUrlCrossRef
  27. 27.↵
    1. Coll F,
    2. Phelan J,
    3. Hill-Cawthorne GA,
    4. Nair MB,
    5. Mallard K,
    6. Ali S,
    7. Abdallah AM,
    8. Alghamdi S,
    9. Alsomali M,
    10. Ahmed AO,
    11. Portelli S,
    12. Oppong Y,
    13. Alves A,
    14. Bessa TB,
    15. Campino S,
    16. Caws M,
    17. Chatterjee A,
    18. Crampin AC,
    19. Dheda K,
    20. Furnham N,
    21. Glynn JR,
    22. Grandjean L,
    23. Ha DM,
    24. Hasan R,
    25. Hasan Z,
    26. Hibberd ML,
    27. Joloba M,
    28. Jones-Lopez EC,
    29. Matsumoto T,
    30. Miranda A,
    31. Moore DJ,
    32. Mocillo N,
    33. Panaiotov S,
    34. Parkhill J,
    35. Penha C,
    36. Perdigao J,
    37. Portugal I,
    38. Rchiad Z,
    39. Robledo J,
    40. Sheen P,
    41. Shesha NT,
    42. Sirgel FA,
    43. Sola C,
    44. Sousa EO,
    45. Streicher EM,
    46. Helden PV,
    47. Viveiros M,
    48. Warren RM,
    49. McNerney R,
    50. Pain A,
    51. Clark TG
    . 2018. Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet 50:307–316. doi:10.1038/s41588-017-0029-0.
    OpenUrlCrossRef
  28. 28.↵
    1. Li H,
    2. Durbin R
    . 2009. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25:1754–1760. doi:10.1093/bioinformatics/btp324.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Li H,
    2. Handsaker B,
    3. Wysoker A,
    4. Fennell T,
    5. Ruan J,
    6. Homer N,
    7. Marth G,
    8. Abecasis G,
    9. Durbin R
    , 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25:2078–2079. doi:10.1093/bioinformatics/btp352.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.↵
    1. McKenna A,
    2. Hanna M,
    3. Banks E,
    4. Sivachenko A,
    5. Cibulskis K,
    6. Kernytsky A,
    7. Garimella K,
    8. Altshuler D,
    9. Gabriel S,
    10. Daly M,
    11. DePristo MA
    . 2010. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20:1297–1303. doi:10.1101/gr.107524.110.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Li H
    . 2011. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics 27:2987–2993. doi:10.1093/bioinformatics/btr509.
    OpenUrlCrossRefPubMedWeb of Science
  32. 32.↵
    1. Hunt M,
    2. Mather AE,
    3. Sanchez-Buso L,
    4. Page AJ,
    5. Parkhill J,
    6. Keane JA,
    7. Harris SR
    . 2017. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. Microb Genom 3:e000131. doi:10.1099/mgen.0.000131.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Feuerriegel S,
    2. Schleusener V,
    3. Beckert P,
    4. Kohl TA,
    5. Miotto P,
    6. Cirillo DM,
    7. Cabibbe AM,
    8. Niemann S,
    9. Fellenberg K
    . 2015. PhyResSE: a Web tool delineating Mycobacterium tuberculosis antibiotic resistance and lineage from whole-genome sequencing data. J Clin Microbiol 53:1908–1914. doi:10.1128/JCM.00025-15.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Feuerriegel S,
    2. Köser CU,
    3. Niemann S
    . 2014. Phylogenetic polymorphisms in antibiotic resistance genes of the Mycobacterium tuberculosis complex. J Antimicrob Chemother 69:1205–1210. doi:10.1093/jac/dkt535.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    1. Merker M,
    2. Kohl TA,
    3. Barilar I,
    4. Andres S,
    5. Fowler PW,
    6. Chryssanthou E,
    7. Angeby K,
    8. Jureen P,
    9. Moradigaravand D,
    10. Parkhill J,
    11. Peacock SJ,
    12. Schon T,
    13. Maurer FP,
    14. Walker T,
    15. Köser C,
    16. Niemann S
    . 2020. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med 12:27. doi:10.1186/s13073-020-00726-5.
    OpenUrlCrossRef
  36. 36.↵
    1. Lee BM,
    2. Harold LK,
    3. Almeida DV,
    4. Afriat-Jurnou L,
    5. Aung HL,
    6. Forde BM,
    7. Hards K,
    8. Pidot SJ,
    9. Ahmed FH,
    10. Mohamed AE,
    11. Taylor MC,
    12. West NP,
    13. Stinear TP,
    14. Greening C,
    15. Beatson SA,
    16. Nuermberger EL,
    17. Cook GM,
    18. Jackson CJ
    . 2020. Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS Pathog 16:e1008287. doi:10.1371/journal.ppat.1008287.
    OpenUrlCrossRef
PreviousNext
Back to top
Download PDF
Citation Tools
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
Martina L. Reichmuth, Rico Hömke, Kathrin Zürcher, Peter Sander, Anchalee Avihingsanon, Jimena Collantes, Chloé Loiseau, Sonia Borrell, Miriam Reinhard, Robert J. Wilkinson, Marcel Yotebieng, Lukas Fenner, Erik C. Böttger, Sebastien Gagneux, Matthias Egger, Peter M. Keller on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA)
Antimicrobial Agents and Chemotherapy Oct 2020, 64 (11) e00513-20; DOI: 10.1128/AAC.00513-20

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients
Martina L. Reichmuth, Rico Hömke, Kathrin Zürcher, Peter Sander, Anchalee Avihingsanon, Jimena Collantes, Chloé Loiseau, Sonia Borrell, Miriam Reinhard, Robert J. Wilkinson, Marcel Yotebieng, Lukas Fenner, Erik C. Böttger, Sebastien Gagneux, Matthias Egger, Peter M. Keller on behalf of the International epidemiology Databases to Evaluate AIDS (IeDEA)
Antimicrobial Agents and Chemotherapy Oct 2020, 64 (11) e00513-20; DOI: 10.1128/AAC.00513-20
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • TEXT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Mycobacterium tuberculosis
delamanid
resistance
mutations
drug resistance
natural polymorphism

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596